Life
    Health

    Prescription pills ‘no better than patches’ for smokers who want to quit

    27 January 2016

    The three most common ways to quit smoking are all equally effective, according to a study published in the online journal JAMA.

    Among adults who wanted to quit smoking, 12 weeks of treatment with a nicotine patch, the drug varenicline, or a combination of patches and lozenges produced no significant differences in rates of smoking abstinence.

    The drug varenicline is prescription-only and is sold as Champix in Britain and as Chantix in the US.

    Researchers from the University of Wisconsin randomly assigned smokers to one of three 12-week smoking cessation pharmacotherapy groups: nicotine patch, varenicline and C-NRT (patches and lozenges). The subjects were also given six counselling sessions. The most common outcome achieved was one full week of abstinence in a period of six months.

    The researchers found that the results were not significantly different at 26 or 52 weeks. Roughly a fifth of the subjects had quit smoking after a year regardless of their treatment.

    The researchers also noted that varenicline produced more frequent side effects, including insomnia, nausea, constipation, sleepiness and indigestion.

    The study’s lead author, Timothy Baker, said: ‘To our knowledge, this open-label study is the first to directly contrast varenicline and C-NRT pharmacotherapies, both with one another and with the nicotine patch. Results showed no significant differences among these three pharmacotherapies in any of the 26- or 52-week abstinence measures.’

    The authors of the study say that, because the treatments differ in cost and regulation, it is important to identify which is most effective for long-term smoking abstinence.

    In Britain a full course of Champix is £17.50 a week, compared to £13 a week for nicotine patches. The Champix label also carries warnings of serious psychiatric side effects and suicidal thoughts.

    Dr Neal Benowitz, a nicotine addiction researcher at the University of California San Francisco, told Reuters it was possible the subjects’ less than a pack-a-day smoking habit and the intense counselling of all participants made it harder to uncover differences between the treatments.